Daraxonrasib has emerged as a significant development in the treatment of stage 4 pancreatic cancer, with clinical trials showing it can double patient survival time from 6.7 months to 13.2 months. According to Dr. Mark Lewis, director of gastrointestinal oncology at Intermountain Health, the medication represents a shift in targeting the KRAS mutation, providing a new option beyond standard intravenous chemotherapy.
Targeted Treatment for KRAS Mutations
Pancreatic cancer remains a leading cause of cancer-related deaths, with approximately 52,000 of the 67,000 Americans diagnosed each year succumbing to the disease, according to the American Cancer Society. The high mortality rate is largely attributed to the lack of early screening and the cancer’s ability to resist traditional therapies by creating a protective shell.
Dr. Lewis noted that daraxonrasib is the first treatment designed to address the KRAS mutation directly. By shutting down the growth signals triggered by this mutation, the drug inhibits the spread of the disease. While surgery remains the only known cure, it is frequently unavailable for patients at stage 4. This new medication is intended to control the disease rather than eliminate it entirely, offering an alternative to the bi-weekly intravenous chemotherapy regimen that has been the standard of care.
Expanded Access and Clinical Availability
Although daraxonrasib has not yet received final approval from the Food and Drug Administration, an application was submitted on July 22. Dr. Lewis anticipates a decision within six to eight weeks. In the interim, Intermountain Health, the Huntsman Cancer Institute, and Utah Cancer Specialists are providing the drug through an Extended Access Program.
Ten Intermountain Health hospitals are currently participating in the program. Dr. Ned Jones, an oncologist in Grand Junction, Colorado, stated that this reach is critical for patients in smaller communities who require access to emerging therapies.
Balancing Efficacy and Side Effects
Patients utilizing the new treatment must weigh its benefits against specific side effects, including diarrhea, mouth sores, and skin rashes. Ben Sasse has publicly discussed his experience with these side effects while participating in clinical trials for the drug.
Dr. Lewis emphasized that the treatment is intended for patients who have not found success or tolerance with standard chemotherapy. Medical professionals, including Dr. Alicia Swink, suggest that the availability of such options provides patients and caregivers with renewed hope as the oncology community continues to refine precision medicine techniques.
Did you know?
Pancreatic cancer is notoriously difficult to detect in its early stages because symptoms often mimic common digestive issues like heartburn or an upset stomach. Weight loss and the sudden onset of diabetes are sometimes the only early indicators.
Frequently Asked Questions
Is daraxonrasib a cure for pancreatic cancer?
No. According to Dr. Mark Lewis, the drug is a treatment designed to control the disease and extend life, but it is not a cure. Surgery remains the only current curative option.
Who is eligible for the Extended Access Program?
The program is limited to specific patients who have been approved by their medical team. It functions similarly to an individual clinical trial and is currently available at select hospitals within the Intermountain Health network.
How does this drug differ from chemotherapy?
While chemotherapy is administered intravenously every two weeks, daraxonrasib is a targeted therapy designed to block the KRAS mutation that drives the growth of most pancreatic cancers.
When will the drug be widely available?
An FDA application was submitted in late July. If approved, the medication could be more broadly accessible to patients within weeks of that decision.
Are you or a loved one navigating a cancer diagnosis? Consult with your oncologist to discuss whether clinical trials or expanded access programs are appropriate options for your specific care plan.
Related reading